載入...
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
With an incidence of 68 new cases per 100,000 people per year, an estimated total number of up to 350,000 new non-small-cell lung cancer (NSCLC) cases are diagnosed each year in the European Union. Up to 10% of NSCLC patients are eligible for therapy with novel ALK (anaplastic lymphoma kinase) inhib...
Na minha lista:
| 發表在: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532624/ https://ncbi.nlm.nih.gov/pubmed/28696381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers9070088 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|